Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant
Latest Information Update: 21 May 2024
At a glance
- Drugs Posoleucel (Primary)
- Indications Adenovirus infections; Cytomegalovirus infections; Epstein-Barr virus infections; Human herpesvirus 6 infections; Polyomavirus infections
- Focus Registrational; Therapeutic Use
- Acronyms Prevent
- Sponsors AlloVir
Most Recent Events
- 04 Feb 2024 This trial has been discontinued in Italy (Global end date: 22 Dec 2023).
- 01 Feb 2024 Status changed from active, no longer recruiting to discontinued.
- 10 Jan 2024 This trial has been completed in Belgium (Global end date: 22 Dec 2023).